TMS Studies & Clinical Results

Dr. Maria Davila’s TMS Studies & Trainings

TMS Studies Published

TMS Trainings

Dr. Davila and the staff attended the Clinical TMS Society conference. They learned from leading TMS researchers and clinicians. Dr. Davila and team presented to the conference the clinical results and research done by the practice.


Dr. Davila and her staff presented CEU’s to over 400 mental health professionals in the Kansas City metro area. Topics discussed included:

  • Screening, Assessment & Brief Intervention of Substance Abuse
  • ASAM and the DSM-V
  • Discussion of Depression and TMS
  • Ethics and Confidentiality

Dr. Edwin A Salsitz, DFASAM, is the chair and presenter for the ASAM ER/LA Opioid REMS course. Led by Dr. Salsitz, the course provided information to medical professionals about handling the opioid epidemic.

The annual meeting of the Clinical TMS Society provides a unique opportunity for people to connect with an international gathering of TMS providers and researchers. Dr. Davila met Dr. Mark George, a lead researcher that allowed TMS to be FDA approved for MDD.
Dr. Davila went to Harvard to receive continued training for noninvasive brain stimulation for treatment of neuropsychiatric disorders such as depression and schizophrenia, epilepsy and chronic pain under the direction of Dr. Alvaro Pascual-Leone. Clinical work also includes studies of central motor conduction time, cortical excitability and noninvasive cortical mapping.
To fully understand TMS, Dr. Davila traveled to MUSC to visit with Dr. Mark George, who led research that allowed TMS to be FDA approved for MDD.

Outside TMS Studies

Evidence of the clinical efficacy of treating patients using TMS therapy in the prefrontal cortex for major depression spans more than 30 randomized, controlled trials in thousands of patients. These reports represent a consistent literature that supports the effectiveness of TMS therapy. TMS therapy was cleared by the FDA in 2008 after a decade of these clinical trials, resulting in the actual administering of TMS being very precise and well-regulated. The TMS clinical results of three separate studies representing a total of 462 patients with treatment performed at over 40 different locations nationwide are shown below.

Study 1: Dunner 2014

DiscoveryMD - Bar graph displaying results of Dunner: A Multisite, Naturalistic, Observational Study of TMS
Click to enlarge

In a naturalistic clinical study in 257 patients who did not benefit from antidepressant medications, TMS therapy offered durable effect over 1 year following acute treatment. The study was conducted at 42 different sites, of which 76% were in private clinical practices, 17% in academic medical centers, and 7% within nonacademic institutional settings. The distribution of practice types participating in the study mirrors those currently offering TMS therapy in the United States. The TMS clinical results were impressive: 67.7% of patients responded to treatment and 45.1% reached remission. 
While the results at the end of the initial treatment (end of acute phase) indicated 
a response rate of 62.3% and a remission rate of 41.2%, the results improved when compared 12 months later. The improvement is partially a result of “reintroduction treatments” that were reintroduced to 36.2% of patients (average of 16 treatments).

Study 2: Vaché 2013

DiscoveryMD - Bar graph displaying results of Austin TMS Clinic for Depression Clinical Study
Click to enlarge

In this study, 82 patients were treated with TMS therapy and evaluated using the IDS-SR30 symptom severity scale immediately before and after treatment. The mean IDS-SR30 symptom severity scale before treatment was 42.8 and reduced to 20.1 at the end of treatment. Fifty percent of the patients included 
in this evaluation had a prior history of hospitalization related to their depressive symptomatology. TMS sessions were conducted 5 days per week for a minimum of 2 weeks with a mean of 32.8 treatments per acute phase. The results were impressive with 55 of the 82 (67.1%) patients positively responding to TMS treatment and with 38 of 82 (46.3%) patients identified to be in remission. Response rates were determined based upon a minimum of a 50% reduction in symptom score compared to the baseline. No significant adverse events were experienced during or after treatment.

Study 3: Cress 2015

DiscoveryMD - Bar graph displaying results of TMS Serenity Center Clinical Study
Click to enlarge

In this study, 123 patients with unipolar, non-psychotic MDD
 who had failed to receive benefit from prior antidepressant treatment were given TMS therapy using the NeuroStar TMS Therapy System (Neuronetics, Inc., Malvern, PA, USA). Patients were treated daily (five days a week for approximately four to six weeks). The study’s primary outcome of interest was the change in depressive symptoms utilizing the Beck Depressive Inventory Scale (BDI II). The mean baseline score was 25.6, indicating moderate depression with a mean end point score of 10.2 by the end of the study, indicating remission. Overall, 89 out of the 123 patients (72.4 percent) achieved remission of symptoms during acute treatment. There were no serious adverse events reported. From this patient population, 10 patients who achieved remission in the acute phase of TMS were evaluated over the course of four years, with over 80.0 percent of patients maintaining remission from their depression.

For more information on past and current clinical trials involving Transcranial Magnetic Stimulation, visit the U.S. National Institutes of Health website.

Get Help Today

Get in touch with DiscoveryMD via phone or filling out the form below.


By clicking submit, I acknowledge that I have read and understand the Privacy Policy

Middle Name of Parent:

*TMS therapy has also undergone, or is currently undergoing, hundreds of clinical trials for the treatment of many other disorders, including: ADD, PTSD, bi-polar disorder, autism, chronic pain, epilepsy, obesity, smoking cessation, Fibromyalgia, Parkinson’s and Alzheimer’s. Many leading medical universities and institutions are involved in these clinical trials, including Columbia, Duke, Harvard, Johns Hopkins, Mayo Clinic, Stanford, UCLA, University of Pennsylvania, and Walter Reed National Military Medical Center.

Call for a Confidential Consultation(888) 526-3066
Call Now Button